| Value | ₹117.9 Cr |
|---|
NSE filing, NSE: MOREPENLAB. Summary written from the filing by ALFA Finder's alert engine.
Morepen Laboratories Ltd: key numbers
- Share price
- ₹119.31
- Market cap
- ₹6,538 Cr
- Revenue (annual)
- ₹1,806 Cr
- Net profit (annual)
- ₹94.88 Cr
- P/E (TTM)
- 34.7×Sector 46.1×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 3.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Morepen Laboratories Ltd
All →Morepen Laboratories Management Change
Morepen Laboratories announced promotions effective 27 October 2026 for two senior management personnel. Charanjeet Chitakara moves to Assistant Vice President (Quality Control) and Vivan Prashar to Vice President (Projects & Engineering).
Morepen Laboratories Other Announcement
Morepen filed its Q2FY27 Monitoring Agency Report confirming Nil deviation in QIP proceeds utilization. The company spent ₹1.12 crore on modernization and expansion during the quarter.
Morepen Laboratories Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs755 Cr (+81%), PAT Rs89 Cr (+117%), EBITDA margin 17.45% (+897bps). H1 revenue Rs1,330 Cr (+57%). CDMO scale-up drives mix.
Morepen Laboratories Results Update
Morepen hit record Q2 FY27 revenue up 81% and EBITDA up 273%, driven by CDMO scale-up. H1 EBITDA reached ₹220 Cr; API+CDMO capacity now 614 KL.
- API + CDMO manufacturing capacity
- 614 KL
Morepen Laboratories Q2 FY27 Results: Net Profit ₹88.9 Cr, Up 117.4% YoY
Morepen Laboratories Ltd reported revenue from operations of ₹746.5 Cr (+81.4% YoY) and net profit of ₹88.9 Cr (+117.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹88.9 Cr · +117.4% YoY
Morepen Laboratories Board Meeting Date
Morepen Laboratories Limited announced a board meeting scheduled for October 27, 2026. The meeting will consider and approve the financial results for the quarter ended September 30, 2026.
Other other announcement announcements
All →Setubandhan Infrastructure Other Announcement
RP informs exchanges that Setubandhan Infrastructure cannot file quarterly compliance documents due to depository fee non-payment. The company remains under CIRP with a pending NCLAT appeal.
Man Infraconstruction Other Announcement
Man Infraconstruction filed a Reg 32 quarterly statement confirming no deviation in use of preferential-warrant proceeds. No deviation or variation arose for the quarter ended September 30, 2026.
Black Buck Other Announcement
BlackBuck's ICRA monitoring agency report for Q1 FY27 confirms IPO proceeds utilization remains in line with stated objects. No deviation was observed in the quarter.
Raama Finance Other Announcement
Raama Finance appointed M/s. Kumar Gaurav & Co. as statutory auditor for three months effective October 29, 2026. The routine appointment carries no financial impact.
Teja Engineering Industries Other Announcement
Teja Engineering Industries filed a non-applicability certificate for Reg 27(2) Corporate Governance for Q1 FY27. As an NSE Emerge-listed SME, the company is exempt from this periodic disclosure.
Prism Medico and Pharmacy Other Announcement
Prism Medico and Pharmacy intimated BSE and MSEI that its corporate website is updated and functional per Regulation 46. This is a routine compliance undertaking with no financial impact.